TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06711887: An Open-label Extension Study to Assess the Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Adult Participants With Lupus Nephritis Who Have Completed Study Treatment in the CVAY736K12301 C

Sponsor: Novartis Pharmaceuticals · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 348 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,218,710

Rescue Site Savings

+$7,397,490

Unlock Full NCT06711887 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06711887 Rescue Dossier →